Importantly, we recently found that BBR effectively inhibits MV4-11 cells, an FMS-like tyrosine kinase 3 (FLT3)-mutated human AML cell line that is resistant to the commonly used anti-leukemia drug cytarabine (Ara-C) [24]. The gene discussed is FLT3; the disease is acute myeloid leukemia.